Provided by Tiger Trade Technology Pte. Ltd.

Prelude Therapeutics Inc

4.38
+0.28006.83%
Post-market: 4.30-0.0800-1.83%16:34 EDT
Volume:3.69M
Turnover:16.09M
Market Cap:348.84M
PE:-4.42
High:4.38
Open:4.08
Low:4.02
Close:4.10
52wk High:5.54
52wk Low:0.7500
Shares:79.64M
Float Shares:8.06M
Volume Ratio:7.58
T/O Rate:45.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9899
EPS(LYR):-1.2929
ROE:-95.25%
ROA:-39.69%
PB:5.80
PE(LYR):-3.39

Loading ...

Company Profile

Company Name:
Prelude Therapeutics Inc
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
79
Office Location:
175 Innovation Boulevard,Wilmington,Delaware,United States
Zip Code:
19805
Fax:
- -
Introduction:
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma. The company is also developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Directors

Name
Position
Kris Vaddi
Chief Executive Officer, Director
David Bonita
Director
Katina Dorton
Director
Martin Babler
Director
Paul A. Friedman
Director
Paul Scherer
Director
Victor Sandor
Director

Shareholders

Name
Position
Kris Vaddi
Chief Executive Officer, Director
Bryant D. Lim
Chief Legal Officer, Corporate Secretary and Chief Financial Officer
Andrew P. Combs
Chief Chemistry Officer
Peggy A. Scherle
Chief Scientific Officer